Stiripentol: Efficacy and Tolerability in Children with Epilepsy

Joëlle Perez; Catherine Chiron; C. Musial; Elisabeth Rey; Henri Bléhaut; P D’Athis; Jean Louis Vincent; Olivier Dulac

doi:10.1111/j.1528-1157.1999.tb02048.x

Abstract

1 min read

STP seems to be a promising add-on drug, particularly when combined with CBZ in patients with partial childhood epilepsy refractory to vigabatrin (VGB) and with CLB in patients with severe myoclonic epilepsy in infancy.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2005

Inhibitory effect of stiripentol on clobazam metabolism by cDNA-expressed human CYP

A. Tran, C Giraud, Elisabeth Rey, Jean Louis Vincent, Jean‐Marc Tréluyer, Gérard Pons

Article2006

Stiripentol in Childhood Partial Epilepsy: Randomized Placebo-Controlled Trial with Enrichment and Withdrawal Design

Catherine Chiron, Sylvie Tonnelier, Elisabeth Rey, M. Brunet, Agnès Tran, Philippe d’Athis, Jean Louis Vincent, Olivier Dulac, Gérard Pons

Article2005

Is pharmacokinetics of stiripentol linear?

Elisabeth Rey, Vincent Jullien, Jean Louis Vincent, Gérard Pons

Article2017

Hierarchical disruption in the Bayesian brain: Focal epilepsy and brain networks

Amir Omidvarnia, Mangor Pedersen, Richard Rosch, Karl Friston, Graeme D. Jackson

Article2014

Efficacy and Safety of Rituximab in Children with Refractory Nephrotic Syndrome; A Multicenter Clinical Trial

Yo Han Ahn, Hee Gyung Kang, Seong Heon Kim, Kyoung Hee Han, Hee Yeon Cho, Jae Il Shin, Min Hyun Cho, Young Seo Park, Su Yung Kim, Seung Joo Lee, Hae Il Cheong, Il Soo Ha